EQRx pursues a market-based model to develop important new, patent-protected medicines and offer them at substantially lower prices than current leading therapies. The company is building a broad pipeline that targets oncology and inflammatory conditions, and highlights late-stage candidates including sugemalimab (PD-L1 antibody), almonertinib (EGFR inhibitor), a PD-1 antibody (formerly CS1003), and lerociclib (CDK4/6 inhibitor). EQRx emphasizes efficiency and proven druggable targets to increase regulatory probability of success and lower the risk-adjusted cost of development. It is also forming deep strategic partnerships and collaborations with national and regional health plans, integrated delivery networks, and health systems to streamline access and prescribing. The company estimates its portfolio could save the U.S. healthcare system 50–70% of current drug spend across the targeted therapeutic areas. Since launching, EQRx has raised significant capital to scale this model and expand its pipeline. EQRx is focused on re-engineering the process from drug discovery to patient delivery to create high-quality, patent-protected medicines more efficiently and cost-effectively. The company intends to leverage advances in science and technology to bring treatments for life-threatening and chronic diseases to patients while pricing therapies dramatically lower than today’s innovative medicines. EQRx positions affordability and accessibility as core attributes of its product strategy, aiming to offer market-based solutions to rising drug costs and to make medicines sustainable for healthcare systems. The company plans to bring together stakeholders across the healthcare system to support discovery, development, and delivery of its therapies. EQRx has assembled a senior team of life sciences leaders, including CEO Alexis Borisy, co-founder Peter Bach, co-founder Sandra Horning, president and COO Melanie Nallicheri, CXO Robert Forrester, and chief communications officer Susan Hager. Headquartered in Cambridge, Massachusetts, EQRx launched with significant institutional backing to support its development and access goals.

Total raised

$700M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2021